Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM
May 25, 2007 (ADA) -- The following is a Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes': Today the New England Journal of Medicine published an article entitled, "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes." The conclusions of this analysis of previous studies of rosiglitazone (brand name, Avandia) suggest that this oral agent used to treat type 2 diabetes may be associated with increased risk of heart attack and death from cardiovascular causes.
According to ACC, ADA and AHA, this study deserves serious thought and follow-up. As estimated here, the overall level of the risk associated with rosiglitazone appears to be small, but nonetheless one that must be considered carefully.
In the meantime, patients using this drug should talk to their health care provider to determine the most appropriate course of action. Patients should not stop taking any prescribed medications without first discussing the issue with their health care provider. Further research will be needed in this area to provide conclusive evidence.
It is very important to prevent diabetes when possible and to effectively treat it when it is present. The treatment of diabetes should be a team approach, with health care providers and patients working together to ensure patient education and empowerment.
The most life-threatening consequences of diabetes are heart disease and stroke, which strike people with diabetes more than twice as often as they do others. If you have diabetes, it is very important to control your blood glucose, blood pressure and cholesterol levels.
Information from the FDA for rosiglitazone can be found at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01636.html.
Comments
thank you for the good ex
thank you for the good explana
Recipes
Nutrition
Diet
Support
dLife Wall
Ask An Expert
dLifeTV
Savings
This Week
My Profile
Home Type 1 Information Type 2 Information Gestational Diabetes Blood Sugar Management Food and Nutrition Inspiration And Expert Advice Watch, Listen, & Learn Daily Living Resources dLife Diet
Get a free blood glucose monitor, recipe newsletters, savings and much more!
Membership is free!
Cardiovascular
Clinical Studies
Complementary Medicine
Complications
Exercise
Food and Nutrition
General
Gestational
Insulin Pumps
Medications
Meters and Test Strips
Obesity
Other
Pregnancy
Product Recalls
Statistics
Technology
Type 1
Type 2
Vision
Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes'
Rosiglitazone -- Seeking a Balanced Approach to Avoid Panic Among Patients
When It Comes to Preventing Amputation in Diabetics, Site, Not Size, Matters
FDA Issues Safety Alert on Avandia
Sleep Apnea Increases Risk of Diabetes and Hypertension in Pregnant Women
Sleep Apnea May Increase Risk of Diabetes
GlaxoSmithKline Strongly Defends its Record on Avandia
Cleveland Clinic Study Shows Commonly Used Diabetes Drug Increases Risk of Heart Attack and Cardiovascular Death
Quality Improvement Effort Pays Off in Diabetes Care
RAND Study Finds Women with Heart Disease and Diabetes Less Likely to Receive Proper Care
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
2005 News Archive
How to Syndicate This Site
Diabetes News from dLife.com
« Rosiglitazone -- Seeking a Balanced Approach to Avoid Panic Among Patients | Main
Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes'
May 25, 2007
Digg This! | Send to Newsvine | Add to del.icio.us
May 25, 2007 (ADA) -- The following is a Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes':
Today the New England Journal of Medicine published an article entitled, "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes." The conclusions of this analysis of previous studies of rosiglitazone (brand name, Avandia) suggest that this oral agent used to treat type 2 diabetes may be associated with increased risk of heart attack and death from cardiovascular causes.
According to ACC, ADA and AHA, this study deserves serious thought and follow-up. As estimated here, the overall level of the risk associated with rosiglitazone appears to be small, but nonetheless one that must be considered carefully.
In the meantime, patients using this drug should talk to their health care provider to determine the most appropriate course of action. Patients should not stop taking any prescribed medications without first discussing the issue with their health care provider. Further research will be needed in this area to provide conclusive evidence.
It is very important to prevent diabetes when possible and to effectively treat it when it is present. The treatment of diabetes should be a team approach, with health care providers and patients working together to ensure patient education and empowerment.
The most life-threatening consequences of diabetes are heart disease and stroke, which strike people with diabetes more than twice as often as they do others. If you have diabetes, it is very important to control your blood glucose, blood pressure and cholesterol levels.
Information from the FDA for rosiglitazone can be found at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01636.html.
Posted by dlifenews at May 25, 2007 09:05 AM
Comments
Post a comment
Name:
Email Address:
URL:
Remember Me? YesNo
Comments:
thank you for the good explanation
Security Code:
Home | Type 1 Diabetes | Type 2 Diabetes | Blood Sugar Management | Support Forums
Food & Recipes | Expert Answers | Events | Diabetes News | Diabetes Research | dLife Today | Advertise at dLife
Corporate Information | dLife Diet Membership Support | Contact dLife.com | Privacy Policy | Editorial Policy | Disclaimer | Logout
Copyright © 2004-2007 LifeMed Media, Inc. All Rights Reserved. tion
My father was assessed at
My father was assessed at the ER for a heart attack (tests proved neg for MI or heart attack) 2 days after he stopped taking this drug (due to not refilling the script). He had.a stress test 4 weeks prior w/great results. The ER doc was confused to say the least, but this article would likely shine some light on the assessment.
The article was of a meta
The article was of a meta-analysis performed on data derived from other studies. No raw data was analyzed directly in this analysis. There are many possible variables and many possible explanations which were not addressed. I am sure that there will be many lawyers more than willing to initiate lawsuits based on this incomplete and and possibly flawed information. The teleologically misleading assumptions will probably not mean much to a perverse judicial reward system motivated more by greed than anything else.
I had a MI on May 25. I h
I had a MI on May 25. I had been on Avandia 8 mg for a number of years. I had stopped taking it two weeks before due to leg swelling in the evenings. I am 55 years old and have no family history of cardiac problems at that age.
Post new comment